🇺🇸 FDA
Pipeline program

Pramipexol Extended Release

248.524

Phase 3 small_molecule completed

Quick answer

Pramipexol Extended Release for Early Parkinson Disease (Early PD) is a Phase 3 program (small_molecule) at Boehringer Ingelheim with 1 ClinicalTrials.gov record(s).

Program details

Company
Boehringer Ingelheim
Indication
Early Parkinson Disease (Early PD)
Phase
Phase 3
Modality
small_molecule
Status
completed

Clinical trials